Spray-drying of inhalable, multifunctional formulations for the treatment of biofilms formed in cystic fibrosis.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Ofosu Kissi, Eric
Elgaher, Walid A M
Schwarz, Bianca C
Hirsch, Anna K H
MetadataShow full item record
AbstractCystic fibrosis (CF) is a serious lung disease, commonly susceptible to Pseudomonas aeruginosa colonization. The dense mucus together with biofilm formation limit drug permeability and prevent the drug from reaching the site of action, causing treatment failure of the bacterial infection. Besides the use of antibiotics, the mucolytic agent N-acetylcysteine (NAC) is recommended to be co-administered in the treatment of CF. Although several formulations have been developed for inhalation therapy to improve the pulmonary condition in CF patients, there is still no comprehensive study on a combined multifunctional dry powder formulation of antibiotics with NAC. In this work, we developed an innovative multifunctional dry powder inhaler (DPI) formulation based on salt formation between NAC and antibiotics and characterized their solid state properties and physical stability. NAC could be spray dried together with three different antibiotics, azithromycin (Azi), tobramycin (Tobra) and ciprofloxacin (Cipro), without the use of organic solvents to form Azi/NAC, Tobra/NAC and Cipro/NAC DPI formulations. Solid-state characterization of these DPI formulations showed that they were amorphous after spray drying. Azi/NAC and Tobra/NAC form co-amorphous salt systems that were physically stable under storage at stress conditions. For particle characterization, the obtained mass median aerodynamic diameters were in a suitable range for inhalation (< 5.0μm). The multifunctional antibiotic/NAC formulations conserved or improved the antibiotic susceptibility and showed promising results regarding the inhibition of P. aeruginosa PA14 biofilm formation.
CitationJournal of controlled release : official journal of the Controlled Release Society.
AffiliationHIPS, Helmholtz-Institut für Pharmazeutische Forschung Saarland, Universitätscampus E8.1 66123 Saarbrücken, Germany.
JournalJournal of controlled release
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 4.0 International
- Spray-dried multidrug particles for pulmonary co-delivery of antibiotics with N-acetylcysteine and curcumin-loaded PLGA-nanoparticles.
- Authors: Lababidi N, Montefusco-Pereira CV, de Souza Carvalho-Wodarz C, Lehr CM, Schneider M
- Issue date: 2020 Dec
- Inhalable antibiotic delivery using a dry powder co-delivering recombinant deoxyribonuclease and ciprofloxacin for treatment of cystic fibrosis.
- Authors: Yang Y, Tsifansky MD, Wu CJ, Yang HI, Schmidt G, Yeo Y
- Issue date: 2010 Jan
- Development, Characterization, and In Vitro Testing of Co-Delivered Antimicrobial Dry Powder Formulation for the Treatment of Pseudomonas aeruginosa Biofilms.
- Authors: Bahamondez-Canas TF, Ferrati S, Moraga-Espinoza DF, Smyth HDC
- Issue date: 2018 Aug
- Clarithromycin and N-acetylcysteine co-spray-dried powders for pulmonary drug delivery: A focus on drug solubility.
- Authors: Manniello MD, Del Gaudio P, Aquino RP, Russo P
- Issue date: 2017 Nov 30
- Inhalable combination powder formulations of phage and ciprofloxacin for P. aeruginosa respiratory infections.
- Authors: Lin Y, Chang RYK, Britton WJ, Morales S, Kutter E, Li J, Chan HK
- Issue date: 2019 Sep